Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cancer patients who are scheduled to receive radiotherapy within the next 3 weeks~  * Total dose at least 2,000 cGy delivered in at least 15 fractions~ * 1 fraction per day, 5 days per week~ * Treatment field to include an area of at least 80 cm2 in the anterior/posterior direction encompassing the upper abdomen~* At risk of developing radiation-induced emesis~* No emesis (retching and/or vomiting) or nausea with severity greater than 2 within the past week~PATIENT CHARACTERISTICS:~Age:~* 16 and over~Performance status:~* ECOG 0-3~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* No jaundice~* No moderate to severe hepatic dysfunction~Renal:~* Not specified~Gastrointestinal:~* No active peptic ulcer~* No lactose intolerance~Other:~* No concurrent condition or illness that contraindicates corticosteroids, serotonin antagonists, or prochlorperazine (e.g., diabetes mellitus)~* No prior unusual or allergic reaction to a serotonin antagonist (ondansetron, dolasetron, or granisetron), corticosteroid, or prochlorperazine~* No condition that would preclude accessibility to treatment or follow-up~* Able and willing to complete diary and quality of life questionnaires in either English or French~* Able to swallow~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* At least 1 week since prior cytotoxic therapy~* No concurrent cytotoxic therapy~Endocrine therapy:~* No concurrent corticosteroids other than topical or inhaled preparations~Radiotherapy:~* See Disease Characteristics~* At least 1 week since prior radiotherapy~* No concurrent cranial radiotherapy~Surgery:~* Not specified~Other:~* At least 2 days since prior medication with antiemetic intent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).